
The Neo-ACT trial

Newsletter, June 2024

Jana de Boniface, Cecilia Ringborg, Renske Altena, Yvonne Wengström and Marie Westman

The Neo-ACT team wishes everyone a wonderful summer!

Inclusion is continuing at a steady pace. We have now included 151 participants with Helsinki being the top recruiting site.









International expansion

The international expansion of the trial is in progress: An agreement with EUBREAST (European Breast Cancer Research Association of Surgical Trialists) is on its way. EUBREAST will coordinate the trial at several German sites that are planned to join during the autumn 2024. Australia under the lead of Eva Zopf has already submitted the ethical applications, and we hope to start three Melbourne sites just after summer.

An additional site in Finland, Turku, will also join. Hopefully, we can soon also welcome sites in Scotland and the UK.

Validation exercise intervention

The updated protocol (version 1.4) has been approved. A substudy will be done to validate the effect of the intervention on levels of physical activity in a group of healthy volumeters.

Amsterdam Cognition Scan

Aims to evaluate changes in cognitive function and the effect of physical exercise. The test is time-consuming for participants, but please encourage them to complete the whole series!



Vetenskapsrådet



tervention during NACT can increase pCR rates in breast cancer.

T Trial link to publication in PLoS [

Homepage our trial homepage.


Contact Trial management marie.westman@cytel.com

Kind regards, The Neo-ACT Team









For any purposes and needs, please visit

https://ki.se/en/meb/the-neo-act-trial



